Clinical trial · Observational
Health and QoL in Oncological Patients: Management of Bone Pathology in Italian Citbl Population
Health and Quality of Life in Oncological Patients: Management of Bone Pathology in the Italian Citbl (Cancer Treatment Induced Bone Loss) Population
NCT04055805CI-TRIAL-00043426unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Female | — | UNRESOLVED | — |
| Osteoporosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Observational Analysis | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (7)
- label
- Fondazione Policlinico Universitario A. Gemelli, Roma
- description
- Polo Scienze della Salute della Donna e del Bambino
- interventionNames
- Behavioral: Observational Analysis
- label
- Università degli Studi di Pavia
- interventionNames
- Behavioral: Observational Analysis
- label
- Università di Napoli "Federico II"
- interventionNames
- Behavioral: Observational Analysis
- label
- Università degli Studi di Siena
- interventionNames
- Behavioral: Observational Analysis
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients willing to provide the Informed consent to participate to the study * Women aged 18-75 years * Patients having breast cancer, with no phenotype restrictions * Patients in natural and stable menopause * Patients having secondary amenorrhea, that arose after the initiation of oncologic treatment, since at least 12 months or 6 months with FSH\> 40 U/I Exclusion Criteria: * Patients with advanced cancer and/or bone metastases and/or visceral metastases * Patients with severe renal insufficiency and/or in dialysis and patients affected by severe endocrine disorders
References
Publications (0)
Data not yet available
No reference posted for this study.